By Tess Stynes
NuVasive Inc. said Chairman and Chief Executive Alex Lukianov
resigned after an investigation overseen by the medical-device
company's board found he didn't comply with some of its expense
reimbursement and other policies.
Shares fell 5.4% to $43.52 in recent premarket trading.
The company also said it expects its first-quarter revenue will
exceed $190 million, above estimates of analysts polled by Thomson
Reuters for $189 million. NuVasive added that it remains on track
to meet its profit guidance for the year.
Greg Lucier, a member of NuVasive's board since 2013, was
appointed as chairman and interim CEO. Mr. Lucier's previous
experience includes serving from May 2003 to February 2014 as
chairman and CEO of Life Technologies, a global life sciences
company acquired by Thermo Fisher Scientific in 2014.
NuVasive said that during Mr. Lucier's 11 years with Life
Technologies, he led the company from being a small startup to a
global biotech firm with nearly $4 billion in sales by 2013.
Regarding the investigation, NuVasive director Jack R. Blair
said that although the amounts involved appear immaterial to the
company's financial results that Mr. Lukianov's actions "in this
regard were not representative of the high standards by which
NuVasive operates."
The disclosure comes a day after Polycom Inc. agreed to pay the
Securities and Exchange Commission $750,000 to settle civil charges
that the tech company had inadequate internal controls and failed
to report to investors that a former chief executive used nearly
$200,000 of corporate funds for personal perks.
Polycom agreed to the settlement without admitting or denying
the SEC's findings. Mr. Miller resigned as Polycom's CEO in July of
2013 after the company's audit committee found irregularities in
his expense reports.
Write to Tess Stynes at tess.stynes@wsj.com
Access Investor Kit for NuVasive, Inc.
Visit
http://www.companyspotlight.com/partner?cp_code=P479&isin=US6707041058
Access Investor Kit for Polycom, Inc.
Visit
http://www.companyspotlight.com/partner?cp_code=P479&isin=US73172K1043
Access Investor Kit for Thermo Fisher Scientific, Inc.
Visit
http://www.companyspotlight.com/partner?cp_code=P479&isin=US8835561023
Subscribe to WSJ: http://online.wsj.com?mod=djnwires